Archived NCCN Tumor Boards: Management of Early-Stage, Invasive, Non-Metastatic Breast Cancer

With the evolving strategies for locoregional management of early-stage breast cancer, the decisions to de-escalate surgery and when to omit axillary lymph node dissection (ALND) and/or sentinel lymph node biopsy (SLNB) and to select the appropriate radiation therapy (RT) dosing should always involve shared decision-making between the patient and clinician, considering the specific tumor biology, other clinical features, and the potential impact on adjuvant systemic therapy decisions. Using a case-based approach can be beneficial to understand the de-escalation approaches in surgery and radiation treatment.
 
The systemic therapy landscape of early-stage breast cancer is also evolving constantly and management is becoming increasingly risk-adapted. The decision-making process of treatment selection should involve careful consideration of the available evidence and a detailed discussion of the associated benefits and risks with patients.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Review new and emerging data in the locoregional management of invasive non-metastatic breast cancer and integrate key findings into clinical practice.
  • Recognize key factors that influence selection of systemic neoadjuvant/adjuvant therapy for patients with non-metastatic breast cancer.
  • Describe how interdisciplinary collaboration among surgeons, radiation oncologists, medical oncologists, and shared-decision with the patient is essential for individualized treatment to optimize outcomes and minimize morbidity. 

You may also be interested in

Recorded Presentations from the NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium

The NCCN 2026 Breast Cancer Congress with Updates from the 2025 San Antonio Breast Cancer Symposium offers expert insights into current recommendations of care for patients with breast cancer and highlights the latest clinical research updates to assist clinicians in formulating breast c
Breast Cancer Case Review

Case-based education can improve personalized treatment decisions, optimize patient outcomes, and enhance the management of late recurrence risk in early breast cancer as well as resistance in advanced disease.
Additional information
Supporters: 
This activity is supported by educational grants from:
  • AstraZeneca
  • Johnson & Johnson
  • Lilly
  • Novartis
  • Nuvalent, Inc. 
Supported by an education grant from Nuvation Bio. 
 
This activity is supported by independent educational grants from:
  • Merck & Co., Inc., Rahway, NJ, USA.
  • Regeneron Pharmaceuticals, Inc. 

Course summary

Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
11/06/2026
Course expires: 
10/30/2027
Part of: 
Archived NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Presenters
Aditya Bardia, MD, MPH
Susie McCloskey, MD, MSHS
Mediget Teshome, MD, MPH
UCLA Jonsson Comprehensive Cancer Center
 
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use.
Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
 
Susie McCloskey, MD, MSHS
 
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
 
Aditya Bardia, MD, MPH
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support 
Bristol Myers Squibb Consulting Fee
Daiichi- Sankyo Co.: Consulting Fee; Grant/Research Support
Eli Lilly and Company: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support 
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support 
Menarini Group, Alyssum Therapeutics, Vyome Therapeutics: Consulting Fee; Grant/Research Support 
Merck & Co., Inc.: Consulting Fee; Grant/Research Support 
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support 
Pfizer Inc.: Consulting Fee; Grant/Research Support
 
Mediget Teshome, MD, MPH 
AstraZeneca Pharmaceuticals LP: Honoraria
 
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products by or on patients.
image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
 
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit.
 
UAN: JA4008196-0000-26-112-H01-P
 
Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 30, 2027. PAs should only claim credit commensurate with the extent of their participation.
 
Case Managers
This program has been pre-approved by The Commission to provide continuing education credit to CCM® Board-Certified Case Managers. The course is approved for 1.0 CE contact hour.
 
Activity Code: S00068964; Approval Number: 260003049
 
To claim these CEs, log into your dashboard at www.yourcommission.org.  

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, you will need: 

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing